Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy

Gain beyond injection

  • Research Highlight
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2017.73.7379 (2017)

Download references

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Gain beyond injection. Nat Rev Clin Oncol 14, 712–713 (2017). https://doi.org/10.1038/nrclinonc.2017.172

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.172

  • Springer Nature Limited

Search

Navigation